secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001104659-25-109146
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theravance Biopharma Q3 2025: YUPELRI net sales hit all-time high $71.4M, achieves non-GAAP breakeven
--------------------------------------------------------------------------------

- YUPELRI net sales all-time high $71.4M (15% YoY); Viatris collaboration revenue $20M (+19%).
- Non-GAAP net income from ops $2.3M (vs -$2.9M); GAAP net income $3.6M (includes $6.5M tax benefit).
- Phase 3 CYPRESS of ampreloxetine (MSA-nOH): open-label done; topline data Q1 2026.
- Cash $333M, no debt; TRELEGY YTD sales on track for $50M milestone in 2025.
- Company achieves non-GAAP breakeven, underscoring financial discipline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465925109146/0001104659-25-109146-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465925109146/tm2530676d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-109146

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer